利湿化瘀方联合亮丙瑞林治疗盆腔子宫内膜异位症的效果及安全性观察  

Observation on the eficacy and safety of Lishi Huayu recipe combined with leuprorelin in the treatment of pelvic endometriosis

作　　者：徐敏[1] 桂香玲 XU Min;GUI Xiangling(Suzhou Hospital of Traditional Chinese Medicine,Suzhou 215000,China)

机构地区：[1]苏州市中医医院,江苏苏州215000

出　　处：《吉林中医药》2023年第11期1311-1315,共5页Jilin Journal of Chinese Medicine

基　　金：江苏省自然科学青年基金项目(BK20200191)。

摘　　要：目的探讨利湿化瘀方联合亮丙瑞林治疗盆腔子宫内膜异位症的临床疗效及安全性。方法选取苏州市中医医院2018年1月-2021年1月收治的80例盆腔子宫内膜异位症患者,采用随机数表法分为观察组和对照组,各40例。对照组给予亮丙瑞林治疗,观察组在对照组基础上联合利湿化瘀方治疗。比较2组临床疗效,评估其中医证候积分以及临床症状、体征评分,测定2组性激素水平[促卵泡生成素(FSH)、促黄体生成素(LH)、雌二醇(E_(2))],记录不良反应以及随访调查复发情况。结果观察组总有效率(95.00%)高于对照组(80.00%)(P<0.05);2组治疗后下腹胀痛、带下量多、神疲乏力、经期延长、舌苔瘀斑、脉弦滑评分低于治疗前(P<0.05),观察组治疗后下腹胀痛、带下量多、神疲乏力、经期延长、舌苔瘀斑、脉弦滑评分低于对照组(P<0.05);2组治疗后盆腔压痛、非经期盆腔痛、痛经、骶韧带触痛结节评分低于治疗前(P<0.05),观察组治疗后盆腔压痛、非经期盆腔痛、痛经、骶韧带触痛结节评分低于对照组(P<0.05);2组治疗后性激素水平低于治疗前(P<0.05),观察组治疗后性激素水平低于对照组(P<0.05);观察组不良反应总发生率(7.50%)低于对照组(25.00%)(P<0.05);观察组复发率13.16%(5/38),对照组复发率34.21%(13/38),2组比较差异有统计学意义(χ^(2)=4.650,P=0.031)。结论利湿化瘀方联合亮丙瑞林较单纯西药能更好改善患者临床症状、体征以及性激素水平,远期疗效较好,且具备安全性。Objective To explore the clinical efficacy and safety of Lishi Huayu recipe combined with leuprorelin in the treatment of pelvic Endometriosis.Methods A total of 80 patients with pelvic endometriosis admitted to our hospital from January 2018 to January 2021 were randomly divided into an observation group and a control group,with 40 cases in each group.The control group was treated with leuprorelin,while the observation group was additionally treated with Lishi Huayu recipe on the basis of the control group.The clinical efficacy of the two groups was compared,and their TCM syndrome scores,clinical symptoms and signs scores were evaluated.In addition,the levels of sex hormones[follicle stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E_(2))]in the two groups were measured.Finally,adverse reactions and the follow-up survey of recurrence were recorded.Results The total effective rate of the observation group(95%)was higher than that of the control group(80%)(P<0.05).After treatment,the scores of lower abdominal distension,excessive vaginal discharge,fatigue,prolonged menstruation,tongue coating ecchymosis,stringy and slippery pulses in the observation group were lower than those in the control group(P<0.05).After treatment,the scores of pelvic tenderness,non-menstrual pelvic pain,dysmenorrhea,and sacral ligament tenderness nodules in the two groups were lower than before treatment(P<0.05),and the above scores in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of sex hormones in the two groups were lower than before treatment(P<0.05),and the levels in the observation group were lower than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group(7.50%)was lower than that in the control group(25.00%)(P<0.05).The recurrence rate in the observation group was 13.16%(5/38),while the recurrence rate in the control group was 34.21%(13/38),with a statistically significant difference between the two groups(χ^(2)=4.650,P-0

关 键 词：利湿化瘀方 亮丙瑞林 盆腔子宫内膜异位症 疗效 安全性 

分 类 号：R711.71[医药卫生—妇产科学]